Carbohydrates are widely used in the development of vaccines and have made great progress. To promote customers' progress in carbohydrate-based vaccine development projects, CD BioGlyco is committed to providing comprehensive scientific services including vaccine design, manufacturing, and quality control.
Carbohydrates represent the most extensive class of biomolecules in nature. They play critical roles in immune system function and can be developed and utilized by the chemical community. Naturally derived glycans, such as cell surface polysaccharides from viruses, bacteria, and parasites, have become valuable antigenic targets for vaccine development.
Currently, the development of natural carbohydrate vaccines is relatively well established. The majority of licensed carbohydrate vaccines such as Salmonella typhi Vi, Haemophilus influenzae type b, Neisseria meningitides and Streptococcus pneumonia belong to this category, where carbohydrate antigens are isolated to form microbial cultures and then bound to carrier proteins. Although they have great efficacy against corresponding pathogens, there are several major problems in vaccine manufacturing, including complex purification procedures, heterogeneous components, impurities, uncontrollable and unproductive protein conjugation chemistry.
Fig.1 Carbohydrate-based vaccines against a variety of diseases. (Hütter, 2015)
Given the difficulties in the development of vaccines based on natural carbohydrates, CD BioGlyco mainly helps customers develop vaccines from the following aspects:
CD BioGlyco has a dedicated research team composed of PhD-level scientists to help clients design and produce carbohydrate-based vaccines with high safety and efficacy. We will do our best to meet your research needs and provide the best service. If you need scientific assistance in vaccine development, please contact us directly and we will respond as soon as possible.